Cerberus Therapeutics utilizes nanobody-based platform to create novel therapeutics for modulating the immune system.

The COVID-19 pandemic highlights the need for safe and accessible therapies to modulate our immune responses. We have developed strategies that allows for precise turning on/off the immune system in response to debilitating diseases.

Our pilot programs focus on autoimmune disorders and infectious diseases, that are based on novel biological discoveries originating from decades of work by our three founders: Dr. Novalia Pishesha, Prof. Hidde Ploegh, and Prof. Harvey Lodish.

Cerberus Therapeutics

Org chart

Teams

Offices